The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Government Contract Win

28 Feb 2013 07:00

RNS Number : 8492Y
Instem plc
28 February 2013
 

28 February 2013

 

Instem plc

("Instem", or, the "Company")

 

US Government Contract Win

 

Provantis Preclinical Software Chosen for National Toxicology Program by National Institute of Environmental Health Sciences

 

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, announced today that the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health (NIH), has purchased the Provantis 9® preclinical software suite via SaaS (Software-as-a-Service) to support National Toxicology Program studies. These Reproductive, Immunotox, Neurobehavioural, Sensitisation and Carcinogenicity studies are primarily carried out at contractor laboratory sites throughout the United States.

 

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further 9 years, giving a possible total contract value for all 10 years of between $6.2m-$7.6m. The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in further material increase in revenue.

 

The National Toxicology Program (NTP) is an interagency program established in 1978 to coordinate toxicology research and development across the Department of Health and Human Services. The program was also created to strengthen the science base in toxicology, develop and validate improved testing methods and provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public.

 

Headquartered at NIEHS, the NTP is managed by the NIEHS and supported by the United States Food and Drug Administration and the Centers for Disease Control and Prevention.

 

Phil Reason, CEO of Instem plc, commented, "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices. Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations, The accessibility of Provantis data will also enable the National Institute of Environmental Health Sciences to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

 

"This long term contract will also provide funding for the development of the Provantis suite in areas specific to the National Toxicology Program, adding further depth to our market leading study management platform and positioning Instem well for anticipated contract extensions and any similar future projects."

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

 

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

 

 

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, Australia, China, India, Singapore and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

About NIEHS

The NIEHS supports research to understand the effects of the environment on human health and is part of the National Institutes of Health (NIH). Its mission is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

 

For more information on environmental health topics, visit www.niehs.nih.gov.

 

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 

This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27320130004C.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDXGDDSBDBGXR
Date   Source Headline
15th Nov 20191:10 pmRNSCompletion of the Acquisition of Leadscope
15th Nov 20197:00 amRNSEarnings Enhancing Acquisition of Leadscope
16th Oct 20197:00 amRNSInformatics Update: Progressive Equity Note
1st Oct 201910:20 amRNSHolding(s) in Company
27th Sep 201912:45 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSHalf-year Report
13th Sep 20197:00 amRNSNotice of Results
15th Jul 20197:00 amRNSHalf Year Trading Update
3rd Jun 20195:06 pmRNSDirector/PDMR Shareholding
31st May 20197:37 amRNSHolding(s) in Company
24th May 20195:03 pmRNSDirector/PDMR Shareholding
23rd May 201911:26 amRNSResult of AGM
2nd May 20194:47 pmRNSPosting of Annual Report & Notice of AGM
29th Apr 20197:00 amRNSExercise of Options and Total Voting Rights
26th Apr 201910:59 amRNSHolding(s) in Company
18th Apr 20192:06 pmRNSSecond Price Monitoring Extn
18th Apr 20192:00 pmRNSPrice Monitoring Extension
15th Apr 20196:03 pmRNSHolding(s) in Company
15th Apr 20195:00 pmRNSHolding(s) in Company
12th Apr 20193:46 pmRNSHolding(s) in Company
12th Apr 201911:58 amRNSHolding(s) in Company
12th Apr 201911:52 amRNSHolding(s) in Company
12th Apr 20197:36 amRNSHolding(s) in Company
11th Apr 20199:49 amRNSResult of Secondary Placing
11th Apr 20197:00 amRNSProposed Placing to Sell 1,660,000 Shares
8th Apr 20196:01 pmRNSHolding(s) in Company
4th Apr 20191:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSNotice of Results
1st Mar 20195:50 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSHolding(s) in Company
28th Feb 201910:35 amRNSIssue of Equity and Total Voting Rights
20th Feb 20191:44 pmRNSExercise of Options, PDMR Dealing and TVR
19th Feb 20192:09 pmRNSDirector/PDMR Shareholding
22nd Jan 20197:00 amRNSTrading Update
7th Dec 20183:28 pmRNSHolding(s) in Company
2nd Oct 20187:00 amRNSExercise of Options and Total Voting Rights
24th Sep 20187:00 amRNSHalf-year Report
10th Sep 20187:00 amRNSNotice of Results
6th Aug 20181:39 pmRNSHolding(s) in Company
23rd Jul 20187:00 amRNSTrading Update
6th Jun 20187:00 amRNSContract win
24th May 201810:43 amRNSResult of AGM
16th May 20183:18 pmRNSNotice of AGM
26th Mar 20187:01 amRNSSEND Contract Extension and SEND Update
26th Mar 20187:00 amRNSFinal Results
16th Mar 20187:00 amRNSNotice of Results
12th Mar 20189:33 amRNSIssue of Equity and TVR
7th Mar 20187:00 amRNSSaaS Business Update
26th Feb 20187:00 amRNSGrants to Directors under the Instem LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.